MONTREAL, QC and WILMINGTON, DE, Dec. 5 /PRNewswire-FirstCall/ -- Millenia Hope (Nachrichten) Biopharma a related company to Millenia Hope Inc. (FRANKFURT: MLF - NASDAQ: OCTBB: MLHP) announced today that it has made a major breakthrough in the cell culture production of Feverfew, a plant whose extracts are used in the cosmetic industry. Feverfew (Tanatecum parthenium) extracts have long been used in natural medicine and the cosmetic industry. However, because of allergic reactions to parthenolide, a major component of the extract, the cosmetic industry has long sought Feverfew extracts that are parthenolide free. Using advanced plant cell culture technologies, Millenia Hope Biopharma has developed a process that produces parthenolide-free extracts. This will make it an ideal ingredient for creams and lotions for the cosmetic industry that focuses on natural plant based ingredients with useful pharmacological properties.
Millenia Hope Biopharma has applied for a patent to protect the industrial process for the production of this novel Feverfew extract. Dr. Bahige M. Baroudy, President and Chief Scientific Officer of Millenia Hope Inc., said, "We are elated that our R&D team was successful in a very short period of time of achieving this milestone of developing an entirely new product. This is a great validation of our Phytomics Technologies. Unlike Feverfew extracts that are obtained directly from plants, our extract is odourless, beige in color and partenolide-free that makes it much more attractive to the cosmetic industry. We have mounted a major endeavour to unravel new properties of our Feverfew extracts. We are confident that this new Feverfew extract will find more applications in the cosmetic industry than already anticipated. Our company and others have been looking for parthenolide-free Feverfew and today's announcement demonstrates our commitment to develop new and practical application of Phytomics, our proprietary plant cell culture platform."
ABOUT MILLENIA HOPE INC&MILLENIA HOPE BIOPHARMA:
Millenia Hope develops innovative treatments and products that enhance the quality of life. We are dedicated to fight major infectious diseases, and promote healthier living. Our team is committed to research and development to deliver on global medical needs and to bring hope through healthcare solutions. Founded in 1997 the company has initially focussed on the need to bring safe and affordable plant based therapies to market for major third world diseases such as malaria and HIV. The first product in this series is Malarex MMH18. Millenia is also pursuing inhibitors of HIV RNase H (patent application pending). Successful development of a drug that targets HIV RNase H will play an important role in the treatment of HIV/AIDS patients who have become resistant to current therapy. http://www.milleniahope.com/
Millenia Hope Biopharma (MHB) a related company to MHI, founded in 2000, is the world's leading bioresearch firm in Phytomic Technologies, commercializing plant cell-based bioprocesses for the discovery, development and production of natural and novel plant-derived products for the pharmaceutical, cosmetic and nutraceutical industries. Avance Pharma has spent over US$25 million in developing its unique proprietary Phytomics Technologies which now belongs to MHB, including the world's largest collection of highly purified phytochemical fractions to be utilized in the pharmaceutical, cosmetic and nutraceutical industry. MHB also provides a plant based drug discovery platform designed for High Throughput Screening and is currently working with a number of leading multinational corporations such as Pierre Fabre Medicaments. http://www.mh-b.com/
SAFE HARBOR STATEMENTS:
Certain statements made in this release may contain language describing the plans, goals, strategies, intentions, forecasts, and expectations of Holley Pharmaceuticals Company Inc. that may be referred to as "forward- looking statements." Several important factors could cause actual results to differ materially from those in such forward-looking statements and Holley Pharmaceuticals Company Inc. could encounter unanticipated obstacles and delays in developing products, services and markets.